Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
NCT ID | NCT05112536 |
Title | Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer |
Recruitment | Active, not recruiting |
Gender | female |
Phase | Phase II |
Variant Requirements | No |
Sponsors | G1 Therapeutics, Inc. |
Indications | |
Therapies |
Cyclophosphamide + Doxorubicin + Pembrolizumab + Trilaciclib |
Age Groups: | senior | adult |
Covered Countries | USA |